^
    Back
    Association details:
    Biomarker:ALK fusion
    Cancer:T Cell Non-Hodgkin Lymphoma
    Drug:Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

    Published date:
    11/06/2019
    Excerpt:
    Preclinical results suggest gilteritinib has therapeutic potential for the treatment of ALCL cells expressing NPM1-ALK and other ALK /ALK-fusion driven hematologic or solid malignancies.
    DOI:
    10.1182/blood-2019-130633